Therapeutic advances in medical oncology · 2026
(Neo)adjuvant therapy patterns and outcomes in patients with HR+/HER2+ early breast cancer: a real-world study using the national cancer information database in China.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhu Jiujun, Jiao Dechuang, Wang Chengzheng, Lu Zhenduo, Chen Xiuchun, Li Lianfang, Sun Xianfu, Zhang Chongjian, Qiao Jianghua, Yan Min, Liu Zhenzhen
Аннотация
BACKGROUND: The introduction of pertuzumab in mainland China in 2019 has significantly altered the treatment practice for early breast cancer; however, comprehensive real-world data on hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-positive (HER2+) patients in this new era remain limited.
OBJECTIVE: To identify the clinicopathological characteristics, (neo)adjuvant treatment patterns, and clinical outcomes in treated patients with HR+/HER2+ early breast cancer in routine clinical practice in China.
DESIGN: A retrospective, observational study was conducted in patients with HR+/HER2+ early breast cancer who underwent surgery for breast cancer and had post-surgical pathologic reports available. De-identified patient data for this multicenter study were obtained from the National Cancer Information Database (NCID) in China.
METHODS: Patients were treated with neoadjuvant and adjuvant therapy with chemotherapy and/or HER2-targeted regimens in clinical practice. The main outcomes and measures were as follows: (neo)adjuvant treatment patterns, total pathologic complete responses (tpCR), breast pathologic complete responses (bpCR), disease-free survival (DFS), and event-free survival (EFS). Two-year DFS and EFS were evaluated using the Kaplan-Meier method. Multivariable logistic and Cox regression analyses were performed to identify associated factors of pCR and survival outcomes, respectively. The median duration of follow-up for the study was 13.9 months (range: 0.1-48.1).
RESULTS: A total of 13,323 patients with HR+/HER2+ early breast cancer were included in this analysis. Trastuzumab + pertuzumab (TP) was the most commonly used regimen in both neoadjuvant and adjuvant settings. Neoadjuvant therapy with dual HER2 blockade resulted in significantly higher tpCR rates (49.1% vs 29.9%) and bpCR rates (53.3% vs 34.4%) compared with trastuzumab alone (both p < 0.001), and numerically higher 2-year DFS rates (90.1% vs 87.1%; p = 0.273) and EFS rates (91.1% vs 89.4%; p = 0.297).
CONCLUSION: The dual HER2 blockade regimens that were widely adopted in China for HR+/HER2+ early breast cancer have demonstrated effectiveness in improving pCR in routine clinical practice; a longer follow‑up is required to validate survival outcomes.
TRIAL REGISTRATION: None.
OBJECTIVE: To identify the clinicopathological characteristics, (neo)adjuvant treatment patterns, and clinical outcomes in treated patients with HR+/HER2+ early breast cancer in routine clinical practice in China.
DESIGN: A retrospective, observational study was conducted in patients with HR+/HER2+ early breast cancer who underwent surgery for breast cancer and had post-surgical pathologic reports available. De-identified patient data for this multicenter study were obtained from the National Cancer Information Database (NCID) in China.
METHODS: Patients were treated with neoadjuvant and adjuvant therapy with chemotherapy and/or HER2-targeted regimens in clinical practice. The main outcomes and measures were as follows: (neo)adjuvant treatment patterns, total pathologic complete responses (tpCR), breast pathologic complete responses (bpCR), disease-free survival (DFS), and event-free survival (EFS). Two-year DFS and EFS were evaluated using the Kaplan-Meier method. Multivariable logistic and Cox regression analyses were performed to identify associated factors of pCR and survival outcomes, respectively. The median duration of follow-up for the study was 13.9 months (range: 0.1-48.1).
RESULTS: A total of 13,323 patients with HR+/HER2+ early breast cancer were included in this analysis. Trastuzumab + pertuzumab (TP) was the most commonly used regimen in both neoadjuvant and adjuvant settings. Neoadjuvant therapy with dual HER2 blockade resulted in significantly higher tpCR rates (49.1% vs 29.9%) and bpCR rates (53.3% vs 34.4%) compared with trastuzumab alone (both p < 0.001), and numerically higher 2-year DFS rates (90.1% vs 87.1%; p = 0.273) and EFS rates (91.1% vs 89.4%; p = 0.297).
CONCLUSION: The dual HER2 blockade regimens that were widely adopted in China for HR+/HER2+ early breast cancer have demonstrated effectiveness in improving pCR in routine clinical practice; a longer follow‑up is required to validate survival outcomes.
TRIAL REGISTRATION: None.